Peak sales of AstraZeneca's Efzimfotase Alfa could hit $3 billion, but only if the drug secures a narrow approval, according to the company's unit chief.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
